Proundly Supported by
Pfizer Foundation
    Home | Current Issue | Past Issue | Board | Instruction | Contact

Treatment of Advanced Non-small Cell Lung Cancer with Vinorelbine in Elderly Thai Patients


Sirikul Sorraritchingchai MD*,
Sumitra Thongprasert MD*, Chaiyuth Charoentum MD*,
Busayamas Chewasakulyong MD*, Suttirak Moonprakan BSc*

* Department of Medicine, Faculty of Medicine, Chiang Mai University


The present study evaluated the efficacy and toxicity of vinorelbine as single chemotherapy for elderly Thai patients with advanced non-small cell lung cancer (NSCLC). Twenty-eight patients with no prior chemotherapy and ECOG performance status of 0-2 were enrolled in the study. There were 20 males and 8 females with a median age of 72 years, and the median ECOG performance status was 1. Eight cases were stage IIIB and 20 cases were stage IV. Fourteen cases were adenocarcinoma, 13 were squamous cell and one was large cell NSCLC. These patients received vinorelbine 25 mg/m2 on day 1 and 8. This treatment produced partial reponse in 5 of 25 evaluable patients (20%). Median survival time was 40 weeks. Hematologic toxicity caused 9% grade 3 anemia, 1.5% grade 4 neutropenia and 0.5% grade 4 neutropenia.
Conclusion : Chemotherapy is a valuable treatment option for elderly patients with advanced NSCLC. Single agent vinorelbine is able to induce an overall response with a low toxicity level in elderly Thai patients with advanced NSCLC

Keyword : Non-Small Cell Lung Cancer, Vinorelbine, Chemotherapy for elderly patients NSCLC

Download Full Paper
  Vol87_No4_367.pdf  [ 81.35 Kb]

Home | Current Issue | Past Issue | Board | Instruction | Contact

© Copyright The Medical Association of Thailand. All Rights Reserved.2001-2002